Abstract
Objectives: A novel drug metarrestin (ML 246) was identified through a screen of compounds that disrupted the perinucleolar compartment (PNC), which is a nuclear structure associated with the metastatic potential of cancer cells. In vivo analyses of various solid tumors show a significant inhibition of distant metastases and reduction in metastatic tumor volume when treated with metarrestin. In this study, the effect of ML246 on ovarian cancer cells was tested in vitro and in vivo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
